The agreement involves Actavis paying approximately GBP 306 million in cash for Auden McKenzie, as well as paying a two-year royalty on a percentage of gross profits of one of Auden Mckenzie’s products.

Actavis is not slowing down on the takeovers front. This latest deal comes hot on the heels of the announcement by Actavis in November 2014 that the company had made a deal to acquire botox maker Allergan for US$66 billion [1]. Other notable deals include its purchase of Irish brand-name drugmaker Warner Chilcott in 2013 [2], specialty drugmaker Forest Laboratories in February 2014 [3] and infectious disease specialist Durata in October 2014.

The deal with Auden McKenzie will add around 175 new brand-name and generic drugs, across a broad spectrum of therapeutic areas, to the existing portfolio of 650 generics Actavis already has in the UK. Auden McKenzie will also add 40 additional products to the pipeline of 85 products that Actavis has under registration and development.

Actavis has diversified into brand-name products as well as strengthening its generics portfolio in recent years. The company has also made a collaboration agreement with biotech giant Amgen for the development and commercialization of several cancer antibody biosimilars [4].

Related article
Actavis agrees to continue making Alzheimer’s drug for now

References
1.   GaBI Online - Generics and Biosimilars Initiative. Actavis buys Allergan and joins pharma top 10 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Feb 6]. Available from: www.gabionline.net/Pharma-News/Actavis-buys-Allergan-and-joins-pharma-top-10 
2.   GaBI Online - Generics and Biosimilars Initiative. Actavis makes definitive agreement with Warner Chilcott [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Feb 6]. Available from: www.gabionline.net/Pharma-News/Actavis-makes-definitive-agreement-with-Warner-Chilcott 
3.   GaBI Online - Generics and Biosimilars Initiative. Actavis to acquire specialty drugmaker Forest Labs [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Feb 6]. Available from: www.gabionline.net/Pharma-News/Actavis-to-acquire-specialty-drugmaker-Forest-Labs 
4.   Biosimilars collaboration at Amgen and Actavis. Generics and Biosimilars Initiative Journal (GaBI Journal). 2014;3(3):155-6. doi:10.5639/gabij.2014.0303.035

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.